New Semaglutide Weight-Loss Pens Arrive in Brazilian Pharmacies Starting at R$ 333

EMS Launches Third Weight Loss Pen as Public Health Discussions Open

Pharmacies in Brazil began stocking a new semaglutide pen priced from 333 reais, marking the arrival of the third weight loss pen from EMS, according to reports. The rollout follows the expiration of the original semaglutide patent in March 2026, which opened the market to multiple synthetic versions of the active pharmaceutical ingredient.

Key Clinical Takeaways:
• The newly launched SemaClique pen requires a dual-copy medical prescription and strict cold-chain storage between 2°C and 8°C.
• Anvisa approved the medication specifically for therapeutic indications that do not include the treatment of general obesity.
• Itaú BBA estimates project the unregulated weight-loss market will reach nearly 19 billion reais in 2026, driven partly by products illegally brought across the border from Paraguay.

Retail Pharmacy Availability Meets Unregulated Market Pressures

While legitimate supply channels expand through domestic production, a parallel underground economy continues to thrive on public demand for rapid weight loss. According to Itaú BBA estimates, products smuggled from Paraguay account for approximately 6.5 billion reais of the projected 19 billion reais total for off-market weight-loss drugs in 2026. This illicit trade flourishes alongside legitimate pharmaceutical expansion, fueled by consumer urgency and hurdles in accessing supervised clinical care.

Regulations shifted rapidly throughout the year following the patent expiration. Anvisa authorized several competing brands in July, including Owozy, Seemasun, Zempneo, Semavy, and Orsema, though not all have reached storefronts. In October, the Semavy brand joined the EMS product Ozivy on pharmacy shelves. Meanwhile, Eurofarma distributes Extensior for type 2 diabetes and Poviztra for obesity and overweight conditions accompanied by comorbidities.

Medication Mimics Natural Hormone to Reduce Appetite

The newly available medication operates by mimicking GLP-1, a natural hormone linked to glucose control and satiety. The active substance reduces appetite and prolongs the sensation of a full stomach. However, the approved labeling for SemaClique specifically excludes obesity treatment. Patients initiating the therapy frequently experience transient gastrointestinal adverse events, including nausea, vomiting, constipation, and abdominal pain during dosage escalation.

Safety guidelines mandate strict adherence to storage parameters, requiring refrigeration between 2°C and 8°C to maintain molecular stability. Dispensing requires a formal two-copy prescription order from a licensed clinician, reflecting the strict regulatory oversight governing injectable incretin mimetics in retail pharmacies.

Parallel Regulatory Milestones in Oral Therapeutics

In a separate regulatory development reported by BBC, Anvisa approved the first oral tablet version of semaglutide on November 4, 2026. Manufactured by Novo Nordisk for adult patients with a body mass index of 30 or higher, the pill shares the active molecule with the injectable pens. Market introduction for the tablet remains pending as the manufacturer awaits a maximum price determination from the Chamber of Regulation of the Market of Medicines. Clinical trial data submitted to regulators indicate that approximately one-third of participants taking the oral formulation achieved a weight reduction of 20 percent or greater, accompanied by improvements in cardiovascular and metabolic markers.

Discussions regarding public sector incorporation remain ongoing. Representatives from the Brazilian Association for the Study of Obesity and Metabolic Syndrome noted that public healthcare integration presents significant initial hurdles, leaving advocacy groups to push for broader inclusion across both public and supplemental health networks. Novo Nordisk has not confirmed whether a price request has been filed with the Chamber of Regulation of the Market of Medicines.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.